New Treatments & Clinical Trials for Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is a fast-moving blood cancer most common in children, where it is often curable, but also affects adults with less favorable outcomes. Intensive chemotherapy cures most children, but adults and patients with high-risk features need better options.

What's actually going on in research

Blinatumomab, a bispecific antibody that forces T-cells to kill leukemia cells, has moved from relapsed disease into front-line treatment, replacing chemotherapy in some patients with B-cell ALL. CAR-T cell therapy for relapsed or refractory B-ALL has shown high remission rates and is being refined for longer durability. Philadelphia chromosome-positive ALL — once very hard to treat — is now approached with tyrosine kinase inhibitors paired with low-intensity or no chemotherapy in many patients.

What to know before you search

Eligibility depends on ALL immunophenotype (B vs. T cell), Philadelphia chromosome status, minimal residual disease level, age, and prior therapy.

What types of trials are currently open

• Treatment trials — Testing new chemotherapy backbones, immunotherapy, or targeted agents in newly diagnosed or relapsed ALL.
• CAR-T trials — Evaluating CAR-T cell therapy in earlier lines of treatment and novel target combinations.
• Pediatric trials — Testing dose-optimized regimens in children and adolescents to reduce late effects while maintaining cure rates.
• Minimal residual disease trials — Using ultra-sensitive leukemia detection to guide treatment decisions and predict relapse.
• Transplant trials — Comparing stem cell transplant timing and conditioning for high-risk ALL.